Ribociclib offers survival benefit in premenopausal women with HR+/HER2- advanced breast cancer

12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.

Related MIMS Drugs

Editor's Recommendations